Compounds of formula (I): EQU R--NH--A--CO--NH--NH--(W).sub.n --Z (I) wherein: PA0 n is 0 or 1, PA0 W represents --CO-- or S(O).sub.r wherein r is 0, 1 or 2, PA0 Z represents a group selected from aryl, arylalkyl, heteroaryl and heteroarylalkyl, each optionally substituted, PA0 R represents a grouping selected from: PA1 Z.sub.1 --T--CO--, Z.sub.1 --O--T--CO--, Z.sub.1 --T--O--CO--, Z.sub.1 --T--S(O).sub.q -- PA1 wherein Z.sub.1, T and q are as defined in the description, PA0 A represents alkylene, alkenylene or alkynylene each having from 3 to 8 carbon atoms, alkylenecycloalkylene, cycloalkylenealkylene, alkylenecycloalkylenealkylene, alkylenearylene, arylenealkylene, alkylenearylenealkylene a grouping ##STR1## wherein PA1 B.sub.1 is as defined in the description, or A forms with the adjacent nitrogen atom a grouping ##STR2## as defined in the description, and medicinal products containing the same which are useful as Neuropeptide Y receptors ligands.

DESCRIPTION OF THE PRIOR ART
 Hydrazide compounds have been described in the literature (J. Org. Chem.,
 1971, 36, 1580) although no pharmacological property has been mentioned.
 Other compounds of related structure are used in the composition of
 photographic films (JP 02008833), or have been used in the formation of
 polymers that are used to prepare semipermeable membranes (J. Appl. Polym.
 Sci., 1992, 44, 1383).
 The compounds of the present invention have a novel structure which imparts
 to them great affinity for neuropeptide Y receptors.
 Ligands of those receptors have been described recently. By way of example,
 there may be mentioned cyclic peptide compounds (WO 9400486), amino acid
 compounds of arginine (WO 9417035), or non-peptide compounds having a
 guanidine group (EP 448765, J. Med. Chem., 1994, 37, 2242).
 BACKGROUND OF THE INVENTION
 Neuropeptide Y (NPY) is a peptide of 36 amino acids, related to the peptide
 YY (PYY) and to pancreatic polypeptides (PP). Originally isolated from pig
 brain (Proc. Natl. Acad. Sci., 1982, 79, 5485), NPY is widely distributed
 in mammals at the level of the central and peripheral nervous systems.
 This neurotransmitter is present in high concentrations in nerve fibres of
 the brain, but also of the heart, the sympathetic ganglia, blood vessels
 and smooth muscles of the vas deferens and of the gastrointestinal tract.
 It is responsible for various physiological effects which are exerted via
 the intermediary of specific receptors (Y). The latter form a
 heterogeneous group, 6 sub-types of which have been identified to date:
 Y.sub.1 to Y.sub.6 (Pharmacological Reviews, 1998, 50, 143). NPY is
 involved in eating behaviour by strongly stimulating food intake (Proc.
 Natl. Acad. Sci., 1985, 82, 3940) or by exerting a regulatory role on the
 HPA (hypothalamic-pituitary-adrenal) axis (J. of Neuroendocrinol., 1995,
 7, 273). It also exhibits anxiolytic and sedative properties
 (Neuropsycho-pharmacology, 1993, 8, 357), a strong vasoconstrictive
 ability (Eur. J. Pharmacol., 1984, 85, 519) which induces an increase in
 blood pressure, and also has an effect on the circadian rhythm
 (Neuroscience and biobehavioral reviews, 1995, 19, 349). In addition to
 the fact that the compounds of the invention are new, they have a
 structure which imparts to them great affinity for NPY receptors. It will
 thus be possible to use them in the treatment of pathologies in which an
 NPY receptor ligand is necessary, especially in the treatment of
 pathologies associated with eating behaviour disorders or energy balance
 disorders, such as diabetes, obesity, bulimia, anorexia nervosa, and also
 in the treatment of arterial hypertension, anxiety, depression, epilepsy,
 sexual dysfunctions and sleep disorders.
 DETAILLED DESCRIPTION OF THE INVENTION
 The present invention relates to compounds of formula (I):
EQU R--NH--A--CO--NH--NH--(W).sub.n --Z (I)
 wherein:
 n is 0 or 1,
 W represents a --CO-- group or an S(O)r group wherein r is 0, 1 or 2,
 Z represents a group selected from optionally substituted aryl, optionally
 substituted arylalkyl, optionally substituted heteroaryl and optionally
 substituted heteroarylalkyl,
 R represents a group selected from:
 Z.sub.1 --T--CO--
 Z.sub.1 --O--T--CO--
 Z.sub.1 --T--O--CO--
 Z.sub.1 --T--S(O).sub.q --
 wherein:
 Z.sub.1 represents an optionally substituted aryl, optionally substituted
 arylalkyl, optionally substituted heteroaryl or optionally substituted
 heteroarylalkyl group,
 T represents a .sigma. bond or an alkylene, alkenylene or alkynylene group,
 q represents an integer 0, 1 or 2,
 A represents a linear or branched alkylene group having from 3 to 8 carbon
 atoms, a linear or branched alkenylene group having from 3 to 8 carbon
 atoms, a linear or branched alkynylene group having from 3 to 8 carbon
 atoms, an alkylenecycloalkylene group, a cycloalkylenealkyene group, an
 alkylenecycloalkylenealkylene group, an alkylenearylene group, an
 arylenealkylene group, an alkylenearylenealkylene group, a grouping
 ##STR3##
 wherein B.sub.1 represents an optionally substituted aryl, optionally
 substituted arylalkyl,optionally substituted heteroaryl or optionally
 substituted heteroarylalkyl group, or A forms with the nitrogen atom a
 grouping
 ##STR4##
 wherein B.sub.2 represents a saturated or unsaturated mono- or bi-cyclic
 system having from 5 to 11 ring members, optionally containing from 1 to 3
 additional hetero atoms selected from nitrogen, oxygen and sulphur,
 with the proviso that when simultaneously n is 0, A represents a grouping
 ##STR5##
 B.sub.1 being a benzyl group, and Z represents an optionally substituted
 phenyl group, then R is other than a benzoyl group,
 their enantiomers, diastereoisomers, and addition salts thereof with a
 pharmaceutically acceptable acid or base,
 it being understood that:
 the term "alkyl" denotes a linear or branched group having from 1 to 6
 carbon atoms,
 the term "alkylene" denotes a linear or branched bivalent radical
 containing from 1 to 6 carbon atoms, unless indicated otherwise,
 the term "alkenylene" denotes a linear or branched bivalent radical
 containing from 2 to 6 carbon atoms and from 1 to 3 double bonds, unless
 indicated otherwise,
 the term "alkynylene" denotes a linear or branched bivalent radical
 containing from 2 to 6 carbon atoms and from 1 to 3 triple bonds, unless
 indicated otherwise,
 the term "aryl" denotes a phenyl, naphthyl, dihydronaphthyl or
 tetrahydronaphthyl group, and the term "arylene" denotes a bivalent
 radical of the same type, the term "heteroaryl" denotes an unsaturated or
 partially unsaturated mono- or bi-cyclic group having from 5 to 11 ring
 members, containing from 1 to 4 hetero atoms selected from nitrogen,
 oxygen and sulphur,
 the term "alkylenecycloalkylene" represents a grouping --A.sub.1 --A.sub.2
 --, the term "cycloalkylene-alkylene" represents a grouping --A.sub.2
 --A.sub.1 --, and the term "alkylenecycloalkylenealkylene" represents a
 grouping --A.sub.1 --A.sub.2 --A.sub.1, the term "alkylenearylene"
 represents a grouping --A.sub.1 --A.sub.3 --, the term "arylenealkylene"
 represents a grouping --A.sub.3 --A.sub.1 --, the term
 "alkylenearylenealkylene" represents a grouping --A.sub.1 --A.sub.3
 --A.sub.1 --, wherein Al is an alkylene group as defined hereinbefore,
 A.sub.2 is a (C.sub.4 -C.sub.8)cycloalkylene group, and A.sub.3 is an
 arylene group as defined hereinbefore,
 the expression "optionally substituted" applied to the terms "aryl",
 "arylalkyl", "heteroaryl" and "heteroarylalkyl" indicates that those
 groups are substituted on their cyclic moiety by from 1 to 5 identical or
 different substituents selected from linear or branched (C.sub.1
 -C.sub.6)alkyl, linear or branched (C.sub.1 -C.sub.6)alkoxy, halogen,
 hydroxy, perhalo-(C.sub.1 -C.sub.6)alkyl in which the alkyl moiety is
 linear or branched, nitro, linear or branched (C.sub.1 -C.sub.6)acyl,
 linear or branched (C.sub.1 -C.sub.6)alkylsulphonyl, and amino (amino
 optionally being substituted by one or two linear or branched (C.sub.1
 -C.sub.6)alkyl and/or linear or branched (C.sub.1 -C.sub.6)acyl groups).
 Among the pharmaceutically acceptable acids, there may be mentioned by way
 of non-limiting example hydrochloric acid, hydrobromic acid, sulphuric
 acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid,
 pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid,
 tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid,
 methanesulphonic acid, camphoric acid, etc.
 Among the pharmaceutically acceptable bases, there may be mentioned by way
 of non-limiting example sodium hydroxide, potassium hydroxide,
 triethylamine, tert-butylamine, etc.
 Advantageously, the invention relates to compounds of formula (I) wherein R
 represents a grouping Z.sub.1 --T--CO, Z.sub.1 preferably being an
 optionally substituted aryl group, and T preferably being an alkylene
 group or a bond.
 Another advantageous aspect of the invention relates to compounds of
 formula (I) wherein R represents a grouping Z.sub.1 --O--T--CO, Z.sub.1
 preferably being an optionally substituted aryl group, and T preferably
 being an alkylene group or a bond.
 Another advantageous aspect of the invention relates to compounds of
 formula (I) wherein R represents a grouping Z.sub.1 --T--O--CO, Z.sub.1
 preferably being an optionally substituted aryl group, and T preferably
 being an alkylene group or a bond.
 Another advantageous aspect of the invention relates to compounds of
 formula (I) wherein R represents a grouping Z.sub.1 --T--S(O).sub.q --,
 Z.sub.1 preferably being an optionally substituted aryl group, and T
 preferably being an alkylene group or a bond, and q preferably being 2.
 The preferred aryl group are phenyl or naphthyl.
 Preferred compounds of the invention are those wherein W represents a
 --CO-- group.
 Other preferred compounds of the invention are those wherein W represents
 an SO.sub.2 group.
 In the preferred compounds of the invention, Z represents a group selected
 from optionally substituted aryl and optionally substituted heteroaryl.
 Preferred compounds of the invention are those wherein A represents a
 grouping
 ##STR6##
 wherein B.sub.1 is an optionally substituted arylalkyl group (for example a
 benzyl or tolylmethyl group).
 Other preferred compounds of the invention are those wherein A represents
 an alkylene-cycloalkylene group (for example methylenecyclohexylene).
 Other preferred compounds of the invention are those wherein A represents
 an alkylenearylene group (for example methylenephenylene).
 In the compounds of the invention, the cyclic groupings
 ##STR7##
 are advantageously selected from pyrrolidine, perhydroindole and piperidine
 groups.
 In an especially advantageous manner, the invention relates to compounds of
 formula (I) wherein W represents a --CO-- group, Z represents a group
 selected from optionally substituted aryl and optionally substituted
 heteroaryl, R represents a grouping selected from Z.sub.1 --T--CO--,
 Z.sub.1 --O--T--CO--, Z.sub.1 --T--O--CO-- and Z.sub.1 --T--S(O).sub.q --
 wherein Z.sub.1 is preferably an optionally substituted aryl or optionally
 substituted heteroaryl group, T represents an alkylene group (for example
 methylene), and q is 2, and A represents an alkylene-cycloalkylene group,
 a grouping
 ##STR8##
 wherein B, is an optionally substituted arylalkyl group,or A forms with the
 adjacent nitrogen atom a pyrrolidine, perhydroindole or piperidine group.
 Among the preferred compounds of the invention, there may be mentioned:
 --N2-({4-[(2-benzoylhydrazino)carbonyl]cyclohexyl}methyl)-2-naphthalenesulp
 honamide
 --N1-({4-[(2-benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-nitrobenzene
 )-sulphonamide
 --N1-[1-benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-1-(4-chlorobenzene)sulphon
 amide.
 The present invention relates also to a process for the preparation of
 compounds of formula (I), characterised in that there is used as starting
 material a compound of formula (II):
EQU H.sub.2 N--A--COOH (II)
 wherein A is as defined for formula (I),
 which is condensed in a basic medium with a halogen compound of formula
 (III):
EQU R--Cl (III)
 wherein R is as defined for formula (I),
 to yield a compound of formula (IV):
EQU R--NH--A--COOH (IV)
 wherein R and A are as defined hereinbefore,
 which compound (IV) is condensed, in the presence of a coupling agent, with
 a monosubstituted hydrazine of formula (V),
EQU H.sub.2 N--NH--(W).sub.n --Z
 wherein n, W and Z are as defined for formula (I),
 to yield compounds of formula (I):
EQU R--NH--A--CO--NH--NH--(W).sub.n --Z (I)
 wherein R, A, n, W and Z are as defined hereinbefore,
 which compound of formula (I):
 may be purified, if necessary, according to a conventional purification
 technique,
 is separated, where appropriate, into its isomers according to a
 conventional separation technique,
 is converted, if desired, into an addition salt thereof with a
 pharmaceutically acceptable acid or base.
 The present invention relates also to pharmaceutical compositions
 comprising as active ingredient at least one compound of formula (I), on
 its own or in combination with one or more inert non-toxic excipients or
 carriers.
 Among the pharmaceutical compositions according to the invention, there may
 be mentioned more especially those that are suitable for oral, parenteral
 or nasal administration, tablets or dragees, sublingual tablets, gelatin
 capsules, lozenges, suppositories, creams, ointments, dermal gels, etc.
 The useful dosage varies according to the age and weight of the patient,
 the nature and severity of the disorder and the route of administration,
 which may be oral, nasal, rectal or parenteral. Generally the unit dose
 ranges from 0.05 to 500 mg for a treatment in from 1 to 3 administrations
 per 24 hours.
 The following Examples illustrate the invention but do not limit it in any
 way. The structures of the compounds described were confirmed by the usual
 spectroscopic techniques. The starting materials used are known products
 or are prepared according to known procedures.

C H N
 % calculated 70.95 5.91 10.79
 % found 71.27 5.90 10.71
 EXAMPLE 2
 Benzyl N-[2-(2-benzoylhydrazino)-1-benzyl-2-oxoethyl]carbamate
 The expected product is obtained according to the process described in
 Example 1, in Step b replacing phenylhydrazine by phenylhydrazide.
 Melting point: 172-174.degree. C.
 Elemental microanalysis:

C H N
 % calculated 69.06 5.52 10.07
 % found 69.14 5.71 9.92
 EXAMPLE 3
 Benzyl N-[1-benzyl-2-oxo-2-(2-nicotinoylhydrazino)ethyl]carbamate
 The expected product is obtained according to the process described in
 Example 1, in Step b replacing phenylhydrazine by
 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 66.03 5.26 13.40
 % found 66.00 5.72 13.68
 EXAMPLE 4
 Benzyl N-{1-benzyl-2-[2-(3-indolyl)acetyl]-2-oxoethyl}carbamate
 The expected product is obtained according to the process described in
 Example 1, in Step b replacing phenylhydrazine by 3-indolylacetohydrazide.
 Elemental microanalysis

C H N
 % calculated 68.94 5.53 11.91
 % found 69.23 5.81 11.57
 EXAMPLE 5
 N1-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-2-phenoxyacetamide
 Step a: 2-[(2-Phenoxyacetyl)amino]-3-phenylpropanoic acid
 A solution of 6.6 mmol (1.0 g) of phenoxyacetic acid in 15 ml of dioxane is
 treated with 49.3 mmol (3.6 ml) of thionyl chloride. The reaction mixture
 is stirred at room temperature for 2 hours and then concentrated. The
 residue, taken up in 10 ml of dichloromethane, and 7.9 mmol (0.3 g) of
 sodium hydroxide in 10 ml of water are added in succession to a solution
 of 7.6 mmol (1.25 g) of phenylalanine and 7.6 mmol (0.3 g) of sodium
 hydroxide in 10 ml of water, the temperature being maintained at
 10.degree. C. The reaction mixture is then stirred for 1 hour at room
 temperature. After decanting, the aqueous phase is washed with
 dichloromethane, and then rendered acidic to pH=2 with a dilute
 hydrochloric acid solution. The precipitate that forms is filtered off and
 recrystallised from water to yield the expected product.
 Step b: N1-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-2-phenoxyacetamide
 3.7 mmol (0.71 g) of EDC are added to a solution, cooled to 0.degree. C.,
 of 3.35 mmol (1 g) of the compound described in the preceding Step and 3.7
 mmol (0.56 g) of HOBT in 15 ml of dichloromethane. After one hour at
 0.degree. C., a solution of 3.7 mmol (0.4 g) of phenylhydrazine in 10 ml
 of dichloromethane is added. The reaction mixture is stirred at 0.degree.
 C. for 1 hour and then at room temperature for 24 hours. The organic phase
 is washed with water, dried over sodium sulphate and concentrated. The
 resulting residue is washed in ether and then filtered to yield the
 expected compound.
 Melting point: 172-175.degree. C.
 Elemental microanalysis:

C H N
 % calculated 70.95 5.91 10.80
 % found 70.91 6.06 10.68
 EXAMPLE 6
 N1-[2-(2-Benzoylhydrazino)-1-benzyl-2-oxoethyl]-2-phenoxyacetamide
 The expected product is obtained according to the process described in
 Example 5, in Step b replacing phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 69.06 5.12 10.07
 % found 68.88 5.52 9.84
 EXAMPLE 7
 N1-{1-Benzyl-2-[2-(2-indolylcarbonyl)hydrazino]-2-oxoethyl}-2-phenoxyacetam
 ide
 The expected product is obtained according to the process described in
 Example 5, in Step b replacing phenylhydrazine by 2-indolecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 68.42 5.26 12.28
 % found 67.97 5.44 12.42
 EXAMPLE 8
 N1-[1-Benzyl-2-oxo-2-(2-nicotinoylhydrazino)ethyl]-2-phenoxyacetamide
 The expected product is obtained according to the process described in
 Example 5, in Step b replacing phenylhydrazine by
 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 64.29 5.36 12.50
 % found 64.06 5.34 12.34
 EXAMPLE 9
 N2-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-2-indole carboxamide
 Step a: 2-(2-Indolylcarbonylamino)-3-phenylpropanoic acid
 The expected product is obtained according to the process described in
 Example 5, Step a, replacing phenoxyacetic acid by 2-indolecarboxylic
 acid.
 Step b: N2-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-2-indolecarboxamide
 The expected product is obtained according to the process described in
 Example 5, Step b, using the compound described in the preceding Step as
 starting material.
 Elemental microanalysis:

C H N
 % calculated 72.36 5.53 14.07
 % found 72.05 5.82 14.60
 EXAMPLE 10
 N2-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-2-naphthalene sulphonamide
 Step a: 2-[(2-Naphthylsulphonyl)amino]-3-phenylpropanoic acid
 A solution of 7.6 mmol (1.71 g) of 2-naphthylsulphonyl chloride in 10 ml of
 dichloro-methane and a solution of 7.9 mmol (0.32 g) of sodium hydroxide
 in 10 ml of water are added slowly in succession to 7.6 mmol (1.25 g) of
 phenylalanine and 7.6 mmol (0.3 g) of sodium hydroxide in 10 ml of water.
 The reaction mixture is stirred for 1 hour at room temperature. After
 decanting, the aqueous phase is washed with dichloromethane and rendered
 acidic to pH=2 with a dilute hydrochloric acid solution. After extraction
 with dichloromethane, the organic phase is dried over sodium sulphate and
 concentrated to yield the expected product.
 Step b:
 N2-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-2-naphthalene-sulphonamide
 The expected product is obtained according to the process described in
 Example 1, Step b, using the compound described in the preceding Step as
 starting material.
 Elemental microanalysis:

C H N
 % calculated 67.41 5.17 9.44
 % found 67.03 5.34 9.57
 EXAMPLE 11
 N2-[2-(2-Benzoylhydrazino)-1-benzyl-2-oxoethyl]-2-naphthalene-sulphonamide
 The expected product is obtained according to the process described in
 Example 1, Step b, using the compound described in Example 10, Step a, as
 starting material, and replacing phenylhydrazine by phenylhydrazide.
 Melting point: 239-240.degree. C.
 Elemental microanalysis:

C H N
 % calculated 65.96 4.86 8.87
 % found 65.55 4.99 8.88
 EXAMPLE 12
 N2-[1-Benzyl-2-oxo-2-(2-phenylhydrazinoethyl]-2-naphthylamide
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing benzyl chloroformate by naphthoyl chloride.
 Elemental microanalysis:

C H N
 % calculated 76.28 5.62 10.27
 % found 76.25 5.76 10.03
 EXAMPLE 13
 N2-[2-(2-Benzoylhydrazino)-1-benzyl-2-oxoethyl]-2-naphthylamide
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing benzyl chloroformate by naphthoyl chloride,
 and in Step b replacing phenyl-hydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 74.17 5.26 9.61
 % found 74.21 5.38 9.49
 EXAMPLE 14
 N2-[1-Benzyl-2-oxo-2-(2-nicotinoylhydrazino)ethyl]-2-naphthylamide
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing benzyl chloroformate by naphthoyl chloride,
 and in Step b replacing phenyl-hydrazine by 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 71.23 5.02 12.79
 % found 70.97 5.38 12.61
 EXAMPLE 15
 N2-{1-Benzyl-2-[2-(2-indolecarbonyl)hydrazino]-2-oxoethyl}-2-naphthylamide
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing benzyl chloroformate by naphthoyl chloride,
 and in Step b replacing phenyl-hydrazine by 2-indolecarbohydrazide.
 Melting point: 214-215.degree. C.
 Elemental microanalysis:

C H N
 % calculated 73.11 5.25 11.76
 % found 72.98 5.16 11.75
 EXAMPLE 16
 N1-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-1-benzene-sulphonamide
 Step a: 2-(Phenylsulphonylamino)-3-phenylpropanoic acid
 A mixture of 151 mmol (26.6 g) of benzenesulphonyl chloride and 50 ml of 4M
 aqueous sodium hydroxide is added to a solution of 37.8 mmol (6.25 g) of
 phenylalanine in 50 ml of 4M aqueous sodium hydroxide. The reaction
 mixture is stirred at room temperature for 24 hours. The solution is then
 rendered acidic to pH=2 with dilute hydrochloric acid and extracted with
 ether. The organic phase is dried over magnesium sulphate and
 concentrated. The resulting residue is recrystallised from ethanol to
 yield the expected compound.
 Step b:
 N1-[1-Benzyl-2-oxo-2-(2-phenylkydrazino)ethyl]-1-benzenesulphonamide
 The expected product is obtained according to the process described in
 Example 1, Step b, using the compound described in the preceding Step as
 starting material.
 Melting point: 162-163.degree. C.
 Elemental microanalysis:

C H N
 % calculated 63.80 5.32 10.63
 % found 63.03 5.38 10.38
 EXAMPLE 17
 N1-[2-(2-Benzoylhydrazino)-1-benzyl-2-oxoethyl]-1-benzene-sulphonamide
 The expected product is obtained according to the process described in
 Example 1, Step b, using the compound of Example 16, Step a, as starting
 material, and replacing phenyl-hydrazine by phenylhydrazide.
 Melting point: 200.degree. C.
 Elemental microanalysis:

C H N
 % calculated 62.41 4.96 9.93
 % found 62.59 5.06 9.84
 EXAMPLE 18
 N1-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-1-(4-chloro-benzene)sulphona
 mide
 The expected product is obtained according to the process described in
 Example 10, in Step a replacing 2-naphthylsulphonyl chloride by
 4-chlorobenzenesulphonyl chloride.
 Melting point: 174-1 75.degree. C.
 Elemental microanalysis:

C H N
 % calculated 58.67 4.66 9.78
 % found 58.63 4.77 9.70
 EXAMPLE 19
 N1-[2-(2-Benzoylhydrazino)-1-benzyl-2-oxoethyl]-1-(4-chloro-benzene)sulphon
 amide
 The expected product is obtained according to the process described in
 Example 10, in Step a replacing 2-naphthylsulphonyl chloride by
 4-chlorobenzenesulphonyl chloride, and in Step b replacing phenylhydrazine
 by phenylhydrazide.
 Melting point: 192-193.degree. C.
 Elemental microanalysis:

C H N
 % calculated 57.70 4.37 9.18
 % found 57.50 4.43 9.14
 EXAMPLE 20
 N1-[1-Benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-1-(3,4-dichloro-benzene)sulp
 honamide
 The expected product is obtained according to the process described in
 Example 16, in Step a replacing benzenesulphonyl chloride by
 3,4-dichlorobenzenesulphonyl chloride.
 Melting point: 164-165.degree. C.
 Elemental microanalysis:

C H N
 % calculated 54.32 4.12 9.05
 % found 54.14 4.16 8.87
 EXAMPLE 21
 N1-[2-(2-Benzoylhydrazino)-1-benzyl-2-oxoethyl-1-(3,4-dichloro-benzene)sulp
 honamide
 The expected product is obtained according to the process described in
 Example 16, in Step a replacing benzenesulphonyl chloride by
 3,4-dichlorobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 200-201.degree. C.
 Elemental microanalysis:

C H N
 % calculated 53.66 3.86 8.54
 % found 53.45 3.93 8.28
 EXAMPLE 22
 Benzyl N-[1-(4-methoxybenzyl)-2-oxo-2-(2-phenylhydrazino)ethyl]-carbamate
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine.
 Melting point: 182-185.degree. C.
 Elemental microanalysis:

C H N
 % calculated 68.74 5.97 10.02
 % found 68.56 6.11 9.81
 EXAMPLE 23
 Benzyl N-[2-benzoylhydrazino-1-(4-methoxybenzyl)2oxoethyl]carbamate
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by phenylhydrazide.
 Melting point: 208-209.degree. C.
 Elemental microanalysis:

C H N
 % calculated 67.11 5.59 9.40
 % found 67.19 5.74 9.32
 EXAMPLE 24
 Benzyl
 N-{2-[2-(24indolylcarbonyl)hydrazino]-1-(4-methoxybenzyl)-2-oxoethyl}carba
 mate
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by 2-indolecarbohydrazide.
 Melting point: 185-186.degree. C.
 Elemental microanalysis:

C H N
 % calculated 66.67 5.35 11.52
 % found 66.40 5.43 12.87
 EXAMPLE 25
 Benzyl
 N-[1-(4-methoxybenzyl)-2-(2-nicotinoylhydrazino)-2-oxoethyl]carbamate
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 64.29 5.36 12.50
 % found 64.43 5.52 12.14
 EXAMPLE 26
 Benzyl
 N-(2-{2-[2-(3-indolyl)acetyl]hydrazino}-1-(4-methoxybenzyl)-2-oxoethyl)car
 bamate
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by 3-indolylacetohydrazide.
 Melting point: 194-195.degree. C.
 Elemental microanalysis:

C H N
 % calculated 67.20 5.60 11.19
 % found 67.01 5.59 11.12
 EXAMPLE 27
 N1-[1-(4-Methoxybenzyl)-2-oxo-2-(2-phenylhydrazino)ethyl]-2-phenoxyacetamid
 e
 The expected product is obtained according to the process described in
 Example 5, in Step a replacing phenylalanine by O-methyltyrosine.
 Elemental microanalysis:

C H N
 % calculated 68.74 5.97 10.02
 % found 68.37 6.06 9.86
 EXAMPLE 28
 N1-[2-(2-Benzoylhydrazino)-1-(4-methoxybenzyl)-2-oxoethyl]-2-phenoxyacetami
 de
 The expected product is obtained according to the process described in
 Example 5, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 67.11 5.59 9.40
 % found 67.19 5.81 9.60
 EXAMPLE 29
 N1-[1-(4-Methoxybenzyl)-2-(2-nicotinoylhydrazino)-2-oxoethyl]-2-phenoxyacet
 amide
 The expected product is obtained according to the process described in
 Example 5, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 64.29 5.36 12.50
 % found 64.06 5.34 12.34
 EXAMPLE 30
 N2-[1-(4-Methoxybenzyl)-2-oxo-2-(2-phenylhydrazino)ethyl]-2-naphthalenesulp
 honamide
 The expected product is obtained according to the process described in
 Example 10, replacing phenylalanine by O-methyltyrosine.
 Melting point: 210-212.degree. C.
 Elemental microanalysis:

C H N
 % calculated 64.47 5.37 8.87
 % found 64.17 5.25 8.56
 EXAMPLE 31
 N2-[2-(2-Benzoylhydrazino)-1-(4-methoxybenzyl)-2-oxoethyl]-2-naphthalenesul
 phonamide
 The expected product is obtained according to the process described in
 Example 10, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by phenylhydrazide.
 Melting point: 246-247.degree. C.
 Elemental microanalysis:

C H N
 % calculated 63.28 5.07 8.20
 % found 63.14 5.01 8.55
 EXAMPLE 32
 N2-[1-(4-Methoxybenzyl)-2-oxo-2-(2-phenylhydrazino)ethyl]-2-naphthylamide
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine and
 benzyl chloroformate by naphthoyl chloride.
 Elemental microanalysis:

C H N
 % calculated 73.80 5.70 9.57
 % found 73.53 5.62 9.54
 EXAMPLE 33
 N2-[1-(4-Methoxybenzyl)-2-(2-nicotinoylhydrazino)-2-oxoethyl]-2-naphthylami
 de
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine and
 benzyl chloroformate by naphthoyl chloride, and in Step b replacing
 phenylhydrazide by 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 69.23 5.13 11.97
 % found 69.25 5.13 11.72
 EXAMPLE 34
 N1-[1-(4-Methoxybenzyl)-2-oxo-2-(2-phenylhydrazino)ethyl]-1-benzenesulphona
 mide
 The expected product is obtained according to the process described in
 Example 16, in Step a replacing L-phenylalanine by O-methyltyrosine.
 Melting point: 163-164.degree. C.
 Elemental microanalysis:

C H N
 % calculated 62.12 5.41 9.88
 % found 61.71 5.54 9.89
 EXAMPLE 35
 N1-[2-(2-Benzoylhydrazino)-1-(4-methoxybenzyl)-2-oxoethyl]-1-benzenesulphon
 amide
 The expected product is obtained according to the process described in
 Example 16, in Step a replacing L-phenylalanine by O-methyltyrosine, and
 in Step b replacing phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 60.85 5.07 6.26
 % found 60.81 5.23 9.20
 EXAMPLE 36
 N1-[1-(4-Methoxybenzyl)-2-oxo-2-(2-phenylhydrazino)ethyl]-1-(4-chlorobenzen
 e)sulphonamide
 The expected product is obtained according to the process described in
 Example 10, in Step a replacing phenylalanine by O-methyltyrosine and
 2-naphthylsulphonyl chloride by 4-chlorobenzenesulphonyl chloride.
 Melting point: 181-183.degree. C.
 Elemental microanalysis:

C H N
 % calculated 56.31 4.92 9.39
 % found 56.64 4.85 9.02
 EXAMPLE 37
 N1-[2-(2-Benzoylhydrazino)-1-(4-methoxybenzyl)-2-oxoethyl]-1-(4-chlorobenze
 ne)sulphonamide
 The expected product is obtained according to the process described in
 Example 10, in Step a replacing phenylalanine by O-methyltyrosine and
 2-naphthylsulphonyl chloride by 4-chlorobenzenesulphonyl chloride, and in
 Step b replacing phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 56.61 4.54 8.61
 % found 56.82 4.55 8.61
 EXAMPLE 38
 N1-[1-(4-Methoxybenzyl)-2-oxo-2-(2-phenylhydrazino)ethyl]-1-(3,4-dichlorobe
 nzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 16, in Step a replacing phenylalanine by O-methyltyrosine and
 benzenesulphonyl chloride by 3,4-dichlorobenzenesulphonyl chloride.
 Melting point: 153-154.degree. C.
 Elemental microanalysis:

C H N
 % calculated 53.44 4.25 8.50
 % found 53.80 4.38 8.30
 EXAMPLE 39
 N1-[2-(2-Benzoylhydrazino)-1-(4-methoxybenzyl)-2-oxoethyl]-1-(3,4-dichlorob
 enzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 16, in Step a replacing phenylalanine by O-methyltyrosine and
 benzenesulphonyl chloride by 3,4-dichlorobenzenesulphonyl chloride, and in
 Step b replacing phenylhydrazine by phenyl-hydrazide.
 Melting point: 214-215.degree. C.
 Elemental microanalysis:

C H N
 % calculated 52.87 4.03 8.05
 % found 52.60 4.09 8.17
 EXAMPLE 40
 N2-[6-Oxo-6-(2-phenylhydrazino)bexyl]-2-naphthalenesulphonamide
 Step a: 6-[(2-Naphthylsulphonyl)amino]hexanoic acid
 30.5 mmol (6.42 g) of 2-naphthylsulphonyl chloride and 15 ml of 4M aqueous
 sodium hydroxide are added in succession to a solution of 15.2 mmol (2 g)
 of 6-aminocaproic acid in 15 ml of 4M aqueous sodium hydroxide. The
 reaction mixture is stirred at room temperature for 24 hours. The solution
 is then rendered acidic to pH=2 with concentrated hydrochloric acid, and
 extracted with dichloromethane. The organic phase is dried over sodium
 sulphate and concentrated, and the resulting residue is recrystallised
 from hexane to yield the expected compound.
 Step b: N2-[6-Oxo-6-(2-phenylhydrazino)hexyl]-2-naphthalenesulphonamide
 The expected product is obtained according to the process described in
 Example 1, Step b, using the compound described in the preceding Step as
 starting material.
 Elemental microanalysis:

C H N
 % calculated 64.16 6.08 10.21
 % found 64.23 5.88 9.95
 EXAMPLE 41
 N2-[6-(2-Benzoylhydrazino)-6-oxohexyl]-2-naphthalene-sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step b replacing phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 62.79 5.69 9.56
 % found 62.50 5.70 9.49
 EXAMPLE 42
 N2-[6-(2-Benzoylhydrazino)-6-oxohexyl]-2-(2-nitrophenyl)-sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 2-naphthylsulphonyl chloride by
 2-nitrophenylsulphonyl chloride.
 Melting point: 106.degree. C.
 Elemental microanalysis:

C H N
 % calculated 52.53 5.10 12.89
 % found 52.61 5.14 12.76
 EXAMPLE 43
 N2-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-2-naphthalenesulphon
 amide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid.
 Elemental microanalysis :(x.sup.1/2 H.sub.2 O)

C H N
 % calculated 64.50 6.27 9.41
 % found 64.54 6.04 9.22
 EXAMPLE 44
 N2-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-2-naphthalenesulpho
 namide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Elemental microanalysis: (x.sup.1/2 H.sub.2 O)

C H N
 % calculated 63.22 5.90 8.85
 % found 63.59 5.68 8.76
 EXAMPLE 45
 N2-[(4-{[2-(2-Indolylcarbonyl)hydrazino]carbonyl}cyclohexyl)-methyl]-2-naph
 thalenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid, and in Step b replacing
 phenylhydrazine by 2-indolylcarbohydrazide.
 Elemental microanalysis: (x.sup.1/2 H.sub.2 O)

C H N
 % calculated 63.11 5.45 10.90
 % found 63.11 5.72 11.10
 EXAMPLE 46
 N2-({4-[(2-Nicotinoylhydrazino)carbonyl]cyclohexyl}methyl)-2-naphthalenesul
 phonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid, and in Step b replacing
 phenylhydrazine by 3-pyridinecarbohydrazide.
 Melting point: 204-205.degree. C.
 Elemental microanalysis:

C H N
 % calculated 61.76 5.57 12.01
 % found 62.15 5.68 11.88
 EXAMPLE 47
 N2-{[4-({2-[2-(3-Indolyl)-acetyl]hydrazino}carbonyl)cyclohexyl]-methyl}-2-n
 aphthalenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid, and in Step b replacing
 phenylhydrazine by 3-indolylacetohydrazide.
 Elemental microanalysis:

C H N
 % calculated 62.61 5.77 10.44
 % found 62.11 5.99 10.41
 EXAMPLE 48
 N1-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-benzylsulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by benzenesulphonyl chloride.
 Melting point: 194-196.degree. C.
 Elemental microanalysis:

C H N
 % calculated 61.99 6.50 10.84
 % found 62.81 6.60 10.83
 EXAMPLE 49
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-benzenesulphonami
 de
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by benzenesulphonyl chloride, and in Step b replacing phenyl-hydrazine by
 phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 60.70 6.06 10.11
 % found 60.25 6.24 10.07
 EXAMPLE 50
 N1-({4-[(2-Nicotinoylhydrazino)carbonyl]cyclohexyl}methyl)-1-benzenesulphon
 amide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by benzenesulphonyl chloride, and in Step b replacing phenyl-hydrazine by
 3-pyridinecarbohydrazide.
 Melting point: 213-215.degree. C.
 Elemental microanalysis: (x.sup.1/2 H.sub.2 O)

C H N
 % calculated 56.41 5.64 13.16
 % found 56.45 5.74 13.56
 EXAMPLE 51
 N1-[(4-{[2-(4-Chlorophenyl)hydrazino]carbonyl}cyclohexyl)methyl]-1-benzenes
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by benzenesulphonyl chloride, and in Step b replacing phenyl-hydrazine by
 4-chlorophenylhydrazine.
 Elemental microanalysis:

C H N
 % calculated 56.93 5.73 9.96
 % found 56.91 5.82 9.86
 EXAMPLE 52
 N1-[(4-{2-(4-Chlorobenzoyl)hydrazino]carbonyl)cyclohexyl)methyl]-1-benzenes
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by benzenesulphonyl chloride, and in Step b replacing phenyl-hydrazine by
 4-chlorophenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 56.01 5.33 9.33
 % found 55.98 5.43 9.41
 EXAMPLE 53
 N1-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-nitrobenzene)su
 lphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-nitrobenzenesulphonyl chloride.
 Elemental microanalysis:

C H N
 % calculated 55.54 5.59 12.95
 % found 55.35 5.49 12.70
 EXAMPLE 54
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-nitrobenzene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-nitrobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Elemental microanalysis: (x.sup.1/2 H.sub.2 O)

C H N
 % calculated 53.72 5.15 11.93
 % found 53.57 5.19 11.76
 EXAMPLE 55
 N1-{[4-(2-[2-(3-Indolyl)-acetyl]hydrazino}carbonyl)cyclohexyl]-methyl}-1-(2
 -nitrobenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-nitrobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 3-indolylacetohydrazide.
 Elemental microanalysis: (x.sup.1/2 H.sub.2 O)

C H N
 % calculated 55.11 5.17 13.39
 % found 55.13 5.14 13.35
 EXAMPLE 56
 N1-[(4-{2-(2-Indolylcarbonyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(2-ni
 trobenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-nitrobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 2-indolylcarbohydrazide.
 Melting point: 249-251.degree. C.
 Elemental microanalysis:

C H N
 % calculated 55.27 5.01 14.02
 % found 55.02 5.28 14.39
 EXAMPLE 57
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-nitro-4-triflu
 oromethylphenyl)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-nitro-4-trifluoromethylphenylsulphonyl chloride, and in Step b
 replacing phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 50.00 4.36 10.61
 % found 49.97 4.46 10.68
 EXAMPLE 58
 N1-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-bromobenzene)su
 lphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-bromobenzenesulphonyl chloride.
 Melting point: 192-194.degree. C.
 Elemental microanalysis:

C H N
 % calculated 50.48 5.05 8.83
 % found 50.38 5.15 8.69
 EXAMPLE 59
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-bromobenzene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-bromobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 251-253.degree. C.
 Elemental microanalysis:

C H N
 % calculated 51.02 4.89 8.50
 % found 50.47 4.92 8.34
 EXAMPLE 60
 N1-[(4-{[2-(4-Chlorophenyl)hydrazino]cyclohexyl}carbonyl)methyl]-1-(4-bromo
 benzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-bromobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazine.
 Elemental microanalysis:

C H N
 % calculated 47.96 4.63 8.39
 % found 47.99 4.63 8.29
 EXAMPLE 61
 N1-[(4-{[2-(4-Chlorobenzoyl)hydrazino]cyclohexyl}carbonyl)methyl]-1-(4-brom
 obenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-bromobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 47.69 4.38 7.95
 % found 47.78 4.45 8.05
 EXAMPLE 62
 N'-Phenyl-1-(phenylsulphonyl)perhydro-2-indolecarbohydrazide
 Step a: 1-(Phenylsulphonyl)-2-perhydroindolecarboxylic acid 29.8 mmol (3.8
 ml) of benzenesulphonyl chloride and 7.4 ml of 4M sodium hydroxide
 solution are added in succession to a solution, cooled to 0.degree. C., of
 29.6 mmol (5 g) of 2-perhydroindolecarboxylic acid in 7.4 ml of 4M NaOH.
 The reaction mixture is left at room temperature, with stirring, for 24
 hours. The mixture is then rendered acidic to pH 2-3 and filtered. The
 resulting solid is washed with ether to yield the expected product.
 Step b: N'-Phenyl-1-phenylsulphonyl)perhydro-2-indolecarbohydrazide
 The expected product is obtained according to the process described in Step
 b of Example 1, using the compound described in the preceding Step as
 starting material.
 Elemental microanalysis:

C H N
 % calculated 63.16 6.27 10.53
 % found 63.37 6.43 10.38
 EXAMPLE 63
 N'-(2-Indolylcarbonyl)-1-(phenylsulphonyl)perhydro-2-indole-carbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step b replacing phenylhydrazine by 2-indolecarbohydrazide.
 Melting point: 134-137.degree. C.
 Elemental microanalysis:

C H N
 % calculated 61.80 5.58 12.02
 % found 61.34 5.74 11.62
 EXAMPLE 64
 N'-Nicotinoyl-1-(phenylsulphonyl)perhydro-2-indolecarbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step b replacing phenylhydrazine by
 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 58.88 5.61 13.08
 % found 58.41 5.74 13.64
 EXAMPLE 65
 N2-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-naphthalenesulphon
 amide
 Step a: 6-(1-Naphthylsulphonyl)aminomethyl]cyclohexanecarboxylic acid
 The expected product is obtained according to the process described in
 Example 40, Step a, replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and using 1-naphthylsulphonyl
 chloride.
 Step b:
 N2-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-naphthalene-sulph
 onamide
 The expected product is obtained according to the process described in
 Example 1, Step b, using the compound described in the preceding Step as
 starting material, and replacing phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 64.44 5.80 9.02
 % found 64.59 5.96 8.76
 EXAMPLE 66
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-isopropylbenze
 ne)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-isopropylbenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 232-236.degree. C.
 Elemental microanalysis:

C H N
 % calculated 62.46 6.77 9.10
 % found 62.32 7.20 9.18
 EXAMPLE 67
 N1-({4-[(2-Naphthoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-nitrobenzene
 )sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-nitrobenzenesulphonyl choride, and in Step b replacing
 phenylhydrazine by 2-naphthylhydrazide.
 Melting point: 263-264.degree. C.
 Elemental microanalysis:

C H N
 % calculated 58.81 5.13 10.97
 % found 58.87 5.32 11.25
 EXAMPLE 68
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(3-nitrobenzene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 54, replacing 2-nitrobenzenesulphonyl chloride by
 3-nitrobenzenesulphonyl chloride.
 Melting point: 198-201.degree. C.
 Elemental microanalysis:

C H N
 % calculated 51.69 4.92 11.48
 % found 51.58 4.83 11.61
 EXAMPLE 69
 N1-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-nitrobenzene)su
 lphonamide
 The expected product is obtained according to the process described in
 Example 53, replacing 2-nitrobenzenesulphonyl chloride by
 4-nitrobenzenesulphonyl chloride.
 Melting point: 200-201.degree. C.
 Elemental microanalysis:

C H N
 % calculated 54.36 5.44 12.68
 % found 53.99 5.33 12.46
 EXAMPLE 70
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-nitrobenzene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 54, replacing 2-nitrobenzenesulphonyl chloride by
 4-nitrobenzenesulphonyl chloride.
 Melting point: 262-264.degree. C.
 Elemental microanalysis:

C H N
 % calculated 53.67 5.11 11.93
 % found 53.68 5.21 11.96
 EXAMPLE 71
 N1-[(4-{[2-(4-Chlorophenyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(4-nitr
 obenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-nitrobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazine.
 Melting point: 211-213.degree. C.
 Elemental microanalysis:

C H N
 % calculated 51.45 4.96 12.00
 % found 51.52 5.12 11.81
 EXAMPLE 72
 N1-[(4-{[2-(4-Chlorobenzoyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(4nitr
 obenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-nitrobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazide.
 Melting point: 272-273.degree. C.
 Elemental microanalysis:

C H N
 % calculated 50.91 4.65 11.31
 % found 50.89 4.76 11.29
 EXAMPLE 73
 N1-({4-[(2-(4-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-bromobenzene
 )sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-bromobenzenesulphonyl chloride.
 Melting point: 165-167.degree. C.
 Elemental microanalysis:

C H N
 % calculated 51.46 5.14 9.01
 % found 51.54 5.29 9.03
 EXAMPLE 74
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-bromobenzene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-bromobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 231-232.degree. C.
 Elemental microanalysis:

C H N
 % calculated 50.97 4.85 8.49
 % found 51.11 4.98 8.51
 EXAMPLE 75
 N1-[(4-{[(2-(4-Chlorophenyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(2-bro
 mobenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-bromobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazine.
 Elemental microanalysis:

C H N
 % calculated 47.92 4.59 8.39
 % found 48.15 4.73 8.37
 EXAMPLE 76
 N1-[(4-{[2-(4-Chlorophenyl)hydrazino]cyclohexyl}carbonyl)-methyl]-1-(2-brom
 obenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-bromobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazide.
 Melting point: 263-264.degree. C.
 Elemental microanalysis:

C H N
 % calculated 47.65 4.35 7.94
 % found 47.65 4.44 7.87
 EXAMPLE 77
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl)methyl)-1-(4-chlorobenzene)
 sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-chlorobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 254-256.degree. C.
 Elemental microanalysis:

C H N
 % calculated 56.01 5.33 9.33
 % found 56.00 5.22 9.24
 EXAMPLE 78
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(3,4-dichlorobenz
 ene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 3,4-dichlorobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 251-252.degree. C.
 Elemental microanalysis:

C H N
 % calculated 52.07 4.75 8.67
 % found 51.91 5.32 8.71
 EXAMPLE 79
 N1-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-fluorobenzene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-fluorobenzenesulphonyl chloride.
 Melting point: 192-193.degree. C.
 Elemental microanalysis:

C H N
 % calculated 59.19 5.92 10.36
 % found 59.03 5.98 10.23
 EXAMPLE 80
 N1-({4-([(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-fluorobenzene
 )sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-fluorobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 264-265.degree. C.
 Elemental microanalysis:

C H N
 % calculated 58.13 5.54 9.69
 % found 58.04 5.60 9.71
 EXAMPLE 81
 N1-[(4-{[2-(4-Chlorophenyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(4-fluo
 robenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-fluorobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazine.
 Melting point: 216-21 7.degree. C.
 Elemental microanalysis:

C H N
 % calculated 54.31 5.20 9.50
 % found 54.39 5.22 9.45
 EXAMPLE 82
 N1-[(4-{[2-(4-Chlorobenzoyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(4-flu
 orobenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-fluorobenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by 4-chlorophenylhydrazide.
 Melting point: 257-258.degree. C.
 Elemental microanalysis:

C H N
 % calculated 53.85 4.92 8.98
 % found 53.90 5.00 8.89
 EXAMPLE 83
 N1-(4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-methylbenzene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-methylbenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 61.52 6.34 9.78
 % found 61.71 6.32 9.67
 EXAMPLE 84
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-methoxybenzene
 )sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-methoxybenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 59.25 6.06 9.43
 % found 59.25 6.26 9.49
 EXAMPLE 85
 N1-({4-[(2-Benzoylhydrazino]carbonyl}cyclohexyl}methyl)-1-(3,4-dimethoxyben
 zene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 3,4-dimethoxybenzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 244-245.degree. C.
 Elemental microanalysis:

C H N
 % calculated 57.02 5.99 8.68
 % found 56.91 6.33 8.84
 EXAMPLE 86
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(4-acetylaminoben
 zene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-(N-acetylamino)benzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 58.46 5.97 11.86
 % found 58.29 6.04 11.73
 EXAMPLE 87
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-methylsulphony
 lbenzene)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 2-(methylsulphonyl)benzenesulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 193-194.degree. C.
 Elemental microanalysis:

C H N
 % calculated 53.55 5.48 8.52
 % found 53.17 5.74 8.49
 EXAMPLE 88
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(.beta.-styrene)s
 ulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by (.beta.-styrene)sulphonyl chloride, and in Step b replacing
 phenylhydrazine by phenylhydrazide.
 Melting point: 208-209.degree. C.
 Elemental microanalysis:

C H N
 % calculated 60.13 6.32 9.15
 % found 60.06 6.45 9.05
 EXAMPLE 89
 N1-({4-[(2-Phenylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-thienyl)sulphon
 amide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by (2-thienyl)sulphonyl chloride.
 Melting point: 218-221.degree. C.
 Elemental microanalysis:

C H N
 % calculated 54.89 5.84 10.67
 % found 54.50 6.05 10.82
 EXAMPLE 90
 N1-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-1-(2-thienyl)sulpho
 namide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by (2-thienyl)sulphonyl chloride, and in Step b replacing phenylhydrazine
 by phenylhydrazide.
 Melting point: 221-222.degree. C.
 Elemental microanalysis:

C H N
 % calculated 52.96 5.34 9.76
 % found 53.14 5.50 9.82
 EXAMPLE 91
 N1-[(4-{[2-(4-Chlorophenyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(2-thie
 nyl)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by (2-thienyl)sulphonyl chloride, and in Step b replacing phenylhydrazine
 by 4-chlorophenylhydrazine.
 Melting point: 193-194.degree. C.
 Elemental microanalysis:

C H N
 % calculated 50.47 5.14 9.81
 % found 50.50 5.27 9.73
 EXAMPLE 92
 N1-[(4-{[(2-(4-Chlorobenzoyl)hydrazino]carbonyl}cyclohexyl)-methyl]-1-(2-th
 ienyl)sulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by (2-thienyl)sulphonyl chloride, and in Step b replacing phenylhydrazine
 by 4-chlorophenylhydrazide.
 Melting point: 237-239.degree. C.
 Elemental microanalysis:

C H N
 % calculated 50.00 4.82 9.21
 % found 49.93 4.97 9.37
 EXAMPLE 93
 N1-[6-Oxo-6-(2-phenylhydrazino)hexyl]-1-benzenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, replacing 2-naphthylsulphonyl chloride by benzenesulphonyl
 chloride.
 Melting point: 123-124.degree. C.
 Elemental microanalysis:

C H N
 % calculated 59.81 6.41 11.62
 % found 59.92 6.58 11.52
 EXAMPLE 94
 N1-[6-(2-Benzoylhydrazino)-6-oxohexyl]-1-phenylsulphonamide
 The expected product is obtained according to the process described in
 Example 40, replacing 2-naphthylsulphonyl chloride by benzenesulphonyl
 chloride, and phenylhydrazine by phenylhydrazide.
 Melting point: 150.degree. C.
 Elemental microanalysis:

C H N
 % calculated 58.59 5.95 10.79
 % found 58.52 6.10 10.90
 EXAMPLE 95
 Benzyl
 N-[1-(4-methoxybenzyl)2-oxo-2-(2-phenylsulphonyl-hydrazino)ethyl]carbamate
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by phenylsulphonylhydrazine.
 Elemental microanalysis:

C H N
 % calculated 59.63 5.18 8.70
 % found 60.03 5.41 8.65
 EXAMPLE 96
 N1-[1-(4-Methoxybenzyl)-2-oxo-2-(2-phenylsulphonylhydrazino)-ethyl]-2-pheno
 xyacetamide
 The expected product is obtained according to the process described in
 Example 5, in Step a replacing phenylalanine by O-methyltyrosine, and in
 Step b replacing phenylhydrazine by phenylsulphonylhydrazine.
 Elemental microanalysis:

C H N
 % calculated 59.63 5.18 8.70
 % found 59.52 5.06 8.59
 EXAMPLE 97
 N1-[1-Benzyl-2-oxo-2-(2-phenylsulphonylhydrazino)ethyl]-1-phenylsulphonamid
 e The expected product is obtained according to the process described in
 Example 10, in Step a replacing 2-naphthylsulphonyl chloride by
 benzenesulphonyl chloride, and in Step b replacing phenylhydrazine by
 phenylsulphonylhydrazine.
 Melting point: 182-183.degree. C.
 Elemental microanalysis:

C H N
 % calculated 54.90 4.58 9.15
 % found 54.70 4.79 8.91
 EXAMPLE 98
 N2-[1-Benzyl-2-oxo-2-(2-phenylsulphonylhydrazino)ethyl]-2-naphthylamide
 The expected product is obtained according to the process described in
 Example 1, in Step a replacing benzyl chloroformate by naphthoyl chloride,
 and in Step b replacing phenylhydrazine by phenylsulphonylhydrazine.
 Elemental microanalysis:

C H N
 % calculated 64.41 4.97 8.35
 % found 63.95 5.01 8.29
 EXAMPLE 99
 1-[(4-Chlorophenyl)sulphonyl]-N'-phenylperhydro-2-indolecarbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing benzenesulphonyl chloride by
 4-chlorobenzenesulphonyl chloride.
 Elemental microanalysis:

C H N
 % calculated 58.13 5.54 9.68
 % found 58.66 5.63 9.18
 EXAMPLE 100
 1-[(4-Chlorophenyl)sulphonyl]-N'-nicotinoyl-perhydro-2-indolecarbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing benzenesulphonyl chloride by
 4-chlorobenzenesulphonyl chloride, and in Step b replacing phenylhydrazine
 by 3-pyridinecarbohydrazide.
 Elemental microanalysis:

C H N
 % calculated 54.49 4.97 12.11
 % found 54.54 5.21 12.32
 EXAMPLE 101
 1-[(2-Nitrophenyl)sulphonyl]-N'-phenylperhydro-2-indolecarbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing benzenesulphonyl chloride by
 2-nitrobenzenesulphonyl chloride.
 Melting point: 86-89.degree. C.
 Elemental microanalysis:

C H N
 % calculated 56.88 5.19 12.64
 % found 56.78 5.49 12.26
 EXAMPLE 102
 N'-Benzoyl-1-[(2-nitrophenyl)sulphonyl]-perhydro-2-indolecarbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing benzenesulphonyl chloride by
 2-nitrobenzenesulphonyl chloride, and in Step b replacing phenylhydrazine
 by phenylhydrazide.
 Melting point: 109-113.degree. C.
 Elemental microanalysis:

C H N
 % calculated 55.93 5.08 11.86
 % found 56.21 5.24 12.05
 EXAMPLE 103
 1-[(4-Chlorophenyl)sulphonyl]-N'-phenyl-2-pyrrolidine carbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing perhydroindolecarboxylic acid by proline
 and benzenesulphonyl chloride by 4-chlorobenzenesulphonyl chloride.
 Melting point: 133-135.degree. C.
 Elemental microanalysis:

C H N
 % calculated 53.75 4.74 11.07
 % found 53.94 4.89 10.81
 EXAMPLE 104
 N'-Benzoyl-1-[(4-chlorophenyl)sulphonyl]-2-pyrrolidine-carbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing perhydroindolecarboxylic acid by proline
 and benzenesulphonyl chloride by 4-chlorobenzenesulphonyl chloride, and in
 Step b replacing phenylhydrazine by phenyl-hydrazide.
 Melting point: 171-172.degree. C.
 Elemental microanalysis:

C H N
 % calculated 53.01 4.42 10.31
 % found 53.26 4.53 10.36
 EXAMPLE 105
 1-[(4-Chlorophenyl)sulphonyl]-N'-nicotinoyl-2-pyrrolidine-carbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing perhydroindolecarboxylic acid by proline
 and benzenesulphonyl chloride by 4-chlorobenzenesulphonyl chloride, and in
 Step b replacing phenylhydrazine by 3-pyridinecarbohydrazide.
 Melting point: 107-108.degree. C.
 Elemental microanalysis:

C H N
 % calculated 49.94 4.16 13.71
 % found 50.51 4.40 13.47
 EXAMPLE 106
 1-[(4-Chlorophenyl)sulphonyl]-N'-naphthyl-2-pyrrolidine carbohydrazide
 The expected product is obtained according to the process described in
 Example 62, in Step a replacing perhydroindolecarboxylic acid by proline
 and phenylhydrazine by naphthylhydrazine.
 Melting point: 178-180.degree. C.
 Elemental microanalysis:

C H N
 % calculated 60.80 4.58 6.76
 % found 60.78 4.73 6.79
 EXAMPLE 107
 N-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-5-(dimethylamino)-1-
 napthalenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-napthylsulphonyl chloride
 by 5-dimethylamino-1-naphthyl sulphonyle chloride and in step b replacing
 phenylhydrazine by phenylhydrazide. Elemental microanalysis:

C H N
 % calculated 61.99 6.50 10.84
 % found 62.81 6.60 10.83
 EXAMPLE 108
 4-Bromo-N-({4-[(2-{[4-(trifluoromethyl)-2-pyrimidinyl]carbonyl}hydrazino)ca
 rbonyl]cyclohexyl}methyl)benzenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 4-bromobenzenesulphonyl chloride and in step b replacing
 phenylhydrazine by 4-(trifluoromethyl)-2-pyrimidinecarbohydrazide.
 Melting point: 229-230.degree. C.
 Elemental microanalysis:

C H N
 % calculated 41,16 4,15 12,64
 % found 41,06 4,03 12,75
 EXAMPLE 109
 3,4-Dimethoxy-N-[(4-{[2-(3-pyridylcarbonyl)hydrazino]carbonyl}cyclohexyl)me
 thyl]benzenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 3,4-dimethoxybenzenesulphonyl chloride and in step b replacing
 phenylhydrazine by 3-pyridinecarbohydrazide.
 Melting point: 211-212.degree. C.
 Elemental microanalysis:

C H N
 % calculated 55,46 5,88 11,76
 % found 55,43 5,75 11,86
 EXAMPLE 110
 N-({4-[(2-Benzoylhydrazino)carbonyl]cyclohexyl}methyl)-5-quinoleinesulphona
 mide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)cyclohexanecarboxylic acid and 2-naphthylsulphonyl chloride
 by 5-quinoleinesulphonyl chloride and in step b replacing phenylhydrazine
 by phenylhydrazide.
 Melting point: 215-216.degree. C.
 Elemental microanalysis:

C H N
 % calculated 61,80 5,58 12,02
 % found 61,69 5,66 12,13
 EXAMPLE 111
 N-{4-[(2-Benzoylhydrazino)carbonyl]benzyl}benzenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)benzoic acid and 2-naphthylsulphonyl chloride by
 benzenesulphonyl chloride and in step b replacing phenylhydrazine by
 phenylhydrazide.
 Melting point: 191-193.degree. C.
 Elemental microanalysis:

C H N
 % calculated 61,54 4,64 10,26
 % found 61,57 4,81 10,22
 EXAMPLE 112
 N2-{4-[(2-Benzoylhydrazino)carbonyl]benzyl}naphthalenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)benzoic acid and 2-naphthylsulphonyl chloride by
 benzenesulphonyl chloride and in step b replacing phenylhydrazine by
 phenylhydrazide.
 Elemental microanalysis:

C H N
 % calculated 65,29 4,57 9,14
 % found 65,69 4,70 8,87
 EXAMPLE 113
 N-{4-[(2-Benzoylhydrazino)carbonyl]benzyl}-2-nitrobenzenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)benzoic acid and 2-naphthylsulphonyl chloride by
 2-nitrobenzenesulphonyl chloride and in step b replacing phenylhydrazine
 by phenylhydrazide.

C H N
 % calculated 55,45 3,96 12,32
 % found 55,36 4,11 12,56
 EXAMPLE 114
 N-{4-[(2-Benzoylhydrazino)carbonyl]benzyl-}-4-bromobenzenesulphonamide
 The expected product is obtained according to the process described in
 Example 40, in Step a replacing 6-aminocaproic acid by
 4-(aminomethyl)benzoic acid and 2-naphthylsulphonyl chloride by
 2-bromobenzenesulphonyl chloride and in step b replacing phenylhydrazine
 by phenylhydrazide.
 Melting point: 208-210.degree. C.
 Elemental microanalysis:

C H N
 % calculated 50,71 3,82 8,45
 % found 50,85 3,61 8,42
 PHARMACOLOGICAL STUDY
 EXAMPLE A
 Measurement of the in vitro affinity for NPY receptors
 The capacity of the compounds of the invention to bind to NPY receptors was
 measured on various cell lines, each expressing one of the receptor
 sub-types studied. Competition binding experiments were carried out using
 the peptide [.sup.125 I]-PYY as radioligand at concentrations ranging from
 15 to 65 pM. The non-specific fraction is measured in the presence of a
 concentration of 1 .mu.M NPY. The cells are incubated for a period ranging
 from 1 to 2 hours depending upon the lines, and the radioactivity is
 collected after filtration over a GF/C filter treated with 0.1% PEI,
 before being measured.
 Results:
 The results are expressed as IC.sub.50. The compounds of the invention
 appear to be capable of significantly displacing the reference ligand: the
 IC.sub.50 values vary from a few nanomoles to some hundreds of nanomoles.
 By way of example, the compound of Example 44 has an IC.sub.50 of 14.5 DM
 for the Y.sub.5 receptor.
 EXAMPLE B
 Measurement of the effect on food intake and weight development in the
 obese mouse
 The compounds of the invention were administered in vivo to the obese ob/ob
 mouse in order to evaluate their influence on food intake and weight
 development. The animals used are 13- to 18-week-old female ob/ob C57B1/6J
 mice. They are divided into groups each comprising 4 animals per cage, the
 cages being fitted with a grating floor, and the mice having free access
 to food. Before the experiments, the animals are conditioned for a period
 ranging from 2 to 3 weeks until their food consumption has stabilised. The
 experiments may be summarised as follows:
 D-14 to D-7: conditioning
 D-7 to D-3: measurement of the basal food intake
 D0 to D+3: animals treated twice daily, the control groups being given the
 carrier
 D0 to D+4: daily measurement of food intake and body weight
 The test products are dissolved, immediately before use, in water, 0.9%
 sodium chloride, propylene glycol or dimethyl sulphoxide, depending upon
 their solubility, and are administered intraperitoneally (IP), in a volume
 of 2.5 ml/kg.
 The parameters measured are the weight of the feed troughs containing the
 food and the body weight.
 Results:
 The results are expressed as:
 percentage variation in food intake under treatment compared with the basal
 food intake;
 percentage variation in body weight between the first and last day of
 treatment.
 By way of example, the results obtained with the compound of Example 44 are
 as follows:

Food intake Body weight
 % variation (D1) % variation
 Product Dose (mg/kg) Control Treated (D4/D0)
 Example 44 5 -25.3 -75.2 -6.0
 EXAMPLE C
 Acute toxicity study
 The acute toxicity was evaluated after oral administration of increasing
 doses of the test compound to groups each comprising 8 mice (26.+-.6
 gramms). The animals were observed at regular intervals over the course of
 the first day and daily for the two weeks following treatment.
 The compounds of the invention appear to be not very toxic at all.
 EXAMPLE D
 Pharmaceutical composition
 Formulation for the preparation of 1000 tablets each comprising a dose of
 10 mg

Compound of Example 44 10 g
 Hydroxypropyl cellulose 2 g
 Wheat starch 10 g
 Lactose 100 g
 Magnesium stearate 3 g
 Talc 3 g